ADITXT, INC.

Create Email Alert

Aditxt is based out of Richmond. Aditx Therapeutics, Inc. operates as a life sciences company. The Company discovers and manufactures immunosuppressive anti-rejection drugs for organ transplantation procedures. Aditx Therapeutics serves customers worldwide. The firm last filed a Form D notice of exempt offering of securities on 2022-08-17. The notice included securities offered of Equity,Debt,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

Contact Info

aditxt, inc.
737 N. FIFTH STREET, SUITE 200
RICHMOND VA    23219
Business Phone: 909-488-0844
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2022-08-17 D BIOTECHNOLOGY Equity,Debt,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 2,200,000 2,033,333 166,667
2021-01-26 D BIOTECHNOLOGY Debt,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security,Other 6,000,000 6,000,000 0
2018-12-26 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 2,000,000 109,800 1,890,200
2018-03-29 D BIOTECHNOLOGY Equity,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 2,000,000 262,500 1,737,500
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
AMRO ALBANNA subscription required
    EXECUTIVE OFFICER DIRECTOR
SHAHROKH SHABAHANG subscription required
    EXECUTIVE OFFICER DIRECTOR
LEONARD BAILEY subscription required
    DIRECTOR
BRIAN BRADY subscription required
    DIRECTOR
CORINNE PANKOVCIN subscription required
    EXECUTIVE OFFICER
ROWENA ALBANNA subscription required
    EXECUTIVE OFFICER
LAURA E. ANTHONY subscription required
    DIRECTOR
NAMVAR KIAIE subscription required
    DIRECTOR
JEFFREY W. RUNGE subscription required
    DIRECTOR
THOMAS J. FARLEY subscription required
    EXECUTIVE OFFICER
MATTHEW SHATZKES subscription required
    EXECUTIVE OFFICER

Elevate your investments